CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026



PacificEdge

CANCER DIAGNOSTICS

Consolidated Interim Financial Statements

	Consolidated Statement of Comprehensive Income	3
	Consolidated Statement of Changes in Equity	4
	Consolidated Balance Sheet	6
	Consolidated Statement of Cash Flows	7

Notes to the Financial Statements

1.	Summary of Accounting Policies	8
2.	Investment and Advances in Subsidiaries	10
3.	Dividends	10
4.	Revenue and Other Income	11
5.	Operating Expenses	12
6.	Segment Information	13
7.	Share Capital	18
8.	Reconciliation of Cash Flows to Operating Activities with Operating Net Loss	19
9.	Net Tangible Assets	20
10.	Contingent Liabilities	20
11.	Capital Commitments	20
12.	Related Parties	20
13.	Local Coverage Determination (LCD) Changes	21
14.	Subsequent Events	21

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

	NOTES	UNAUDITED SEPT 2026 6 MONTHS ($000)	UNAUDITED SEPT 2025 6 MONTHS ($000)	AUDITED MARCH 2026 12 MONTHS ($000)
REVENUE				
Operating Revenue	4	5,856	5,939	11,499
Total Operating Revenue		**5,856**	**5,939**	**11,499**
Other Income	4	743	897	1,513
Interest Income		384	299	521
Foreign Exchange Gain (Loss)		28	(12)	(20)
Net Fair Value Gain (Loss) on Derivatives at Fair Value Through Profit and Loss		(34)	-	67
Total Revenue and Other Income		**6,977**	**7,123**	**13,580**
OPERATING EXPENSES				
Laboratory Operations		5,866	5,884	11,606
Research		6,762	7,065	13,431
Sales and Marketing		5,371	8,453	15,218
General and Administration		3,708	4,837	9,103
Total Operating Expenses	5	**21,707**	**26,239**	**49,358**
NET LOSS BEFORE TAX		**(14,730)**	**(19,116)**	**(35,778)**
Income Tax Expense		-	-	-
LOSS FOR THE PERIOD AFTER TAX		**(14,730)**	**(19,116)**	**(35,778)**
Items that may be reclassified to profit or loss:				
Translation of Foreign Operations		48	(82)	(186)
TOTAL COMPREHENSIVE LOSS attributable to equity holders of the Company		**(14,682)**	**(19,198)**	**(35,964)**
Earnings per share for loss attributable to the equity holders of the Company during the period				
Basic and Diluted Earnings per share	7	(0.012)	(0.022)	(0.038)

Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2026

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

	NOTES	SHARE CAPITAL ($000)	ACCUMULATED LOSSES ($000)	SHARE BASED PAYMENTS RESERVE ($000)	FOREIGN CURRENCY TRANSLATION RESERVE ($000)	TOTAL EQUITY ($000)
UNAUDITED 6 MONTHS TO 30 SEPTEMBER 2025						
Balance as at 31 March 2025		**294,458**	**(276,222)**	**6,860**	**989**	**26,085**
(Loss) After Tax		-	(19,116)	-	-	(19,116)
Other Comprehensive Income		-	-	-	(82)	(82)
Total Comprehensive Loss attributable to equity holders of the Company		-	(19,116)	-	(82)	(19,198)
Transactions with owners in their capacity as owners:						
Issue of Share Capital (net of issue costs)	7	19,548	-	-	-	19,548
Share Based Payments - Employee Remuneration	7	77	-	-	-	77
Share Based Payment - Employee Share Options	7	-	63	321	-	384
Balance as at 30 September 2025		**314,083**	**(295,275)**	**7,181**	**907**	**26,896**
AUDITED 12 MONTHS TO 31 MARCH 2026						
Balance as at 31 March 2025		**294,458**	**(276,222)**	**6,860**	**989**	**26,085**
(Loss) After Tax		-	(35,778)	-	-	(35,778)
Other Comprehensive Income		-	-	-	(186)	(186)
Total Comprehensive Loss attributable to equity holders of the Company		-	(35,778)	-	(186)	(35,964)
Transactions with owners in their capacity as owners:						
Issue of Share Capital (net of issue costs)		19,547	-	-	-	19,547
Share Based Payments - Employee Remuneration	7	121	-	-	-	121
Share Based Payment - Employee Share Options	7	31	122	717	-	870
Balance as at 31 March 2026		**314,157**	**(311,878)**	**7,577**	**803**	**10,659**
UNAUDITED 6 MONTHS TO 30 SEPTEMBER 2026						
Balance as at 31 March 2026		**314,157**	**(311,878)**	**7,577**	**803**	**10,659**
(Loss) After Tax		-	(14,730)	-	-	(14,730)
Other Comprehensive Income		-	-	-	48	48
Total Comprehensive Loss attributable to equity holders of the Company		-	(14,730)	-	48	(14,682)
Transactions with owners in their capacity as owners:						
Issue of Share Capital (net of issue costs)	7	34,704	-	-	-	34,704
Share Based Payments - Employee Remuneration	7	1,132	-	-	-	1,132
Share Based Payment - Employee Share Options	7	6	71	373	-	450
Balance as at 30 September 2026		**349,999**	**(326,537)**	**7,950**	**851**	**32,263**

Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.

CONSOLIDATED BALANCE SHEET

AS AT 30 SEPTEMBER 2026

	NOTES	UNAUDITED SEPT 2026 6 MONTHS ($000)	UNAUDITED SEPT 2025 6 MONTHS ($000)	AUDITED MARCH 2026 12 MONTHS ($000)
CURRENT ASSETS				
Cash and Cash Equivalents		13,370	15,121	7,776
Short Term Deposits		16,000	7,000	-
Receivables		2,594	3,753	2,460
Inventory		1,732	1,933	2,039
Derivative Financial Instrument		32	-	67
Other Assets		1,490	1,773	1,431
Total Current Assets		**35,218**	**29,580**	**13,773**
NON-CURRENT ASSETS				
Property, Plant and Equipment		1,978	2,583	2,218
Right of Use Assets		541	1,893	1,189
Intangible Assets		343	608	422
Total Non-Current Assets		**2,862**	**5,084**	**3,829**
TOTAL ASSETS		**38,080**	**34,664**	**17,602**
CURRENT LIABILITIES				
Payables and Accruals		5,026	5,446	5,658
Borrowings		225	300	-
Lease Liabilities		539	1,471	1,159
Total Current Liabilities		**5,790**	**7,217**	**6,817**
NON-CURRENT LIABILITIES				
Lease Liabilities		27	551	126
Total Non-Current Liabilities		**27**	**551**	**126**
TOTAL LIABILITIES		**5,817**	**7,768**	**6,943**
NET ASSETS		**32,263**	**26,896**	**10,659**
Represented by:				
EQUITY				
Share Capital	7	349,999	314,083	314,157
Accumulated Losses		(326,537)	(295,275)	(311,878)
Share Based Payments Reserve		7,950	7,181	7,577
Foreign Translation Reserve		851	907	803
TOTAL EQUITY		**32,263**	**26,896**	**10,659**
FURTHER INFORMATION:				
Net Tangible Assets Per Share ($)	9	0.026	0.026	0.010



For and on behalf of the Board of Directors:

Director

Dated 23rd day of November 2026

Director

Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

	NOTES	UNAUDITED SEPT 2026 6 MONTHS ($000)	UNAUDITED SEPT 2025 6 MONTHS ($000)	AUDITED MARCH 2026 12 MONTHS ($000)
CASH FLOWS TO OPERATING ACTIVITIES				
Cash was provided from:				
Receipts from Customers		6,024	7,985	13,230
Receipts from Research Tax Incentives and Grant Providers		678	-	2,110
Interest Received		181	427	698
		6,883	8,412	16,038
Cash was disbursed to:				
Payments to Suppliers and Employees		19,180	27,393	47,996
Net GST		33	45	(20)
		19,213	27,438	47,976
Net Cash Flows To Operating Activities	8	**(12,330)**	**(19,026)**	**(31,938)**
CASH FLOWS FROM (TO) INVESTING ACTIVITIES				
Cash was provided from:				
Proceeds from Short Term Deposits		14,500	15,086	22,086
		14,500	15,086	22,086
Cash was disbursed to:				
Purchase of Short Term Deposits		30,500	9,000	9,000
Capital Expenditure on Plant and Equipment		148	51	117
Capital Expenditure on Intangible Assets		18	14	15
		30,666	9,065	9,132
Net Cash Flows From (To) Investing Activities		**(16,166)**	**6,021**	**12,954**
CASH FLOWS FROM FINANCING ACTIVITIES				
Cash was received from:				
Ordinary Shares Issued		36,050	20,825	20,676
Proceeds from Borrowings		508	-	-
Exercising of Share Options		1	-	-
		36,559	20,825	20,676
Cash was disbursed to:				
Security deposited for Credit Cards		15	-	-
Repayment of Borrowings		283	-	300
Repayment of Leases - Principal		778	686	1,426
Repayment of Leases - Interest		30	76	130
Issue Expenses		1,431	1,338	1,339
		2,537	2,100	3,195
Net Cash Flows From Financing Activities		**34,022**	**18,725**	**17,481**
Net Increase (Decrease) in Cash Held		**5,526**	**5,720**	**(1,503)**
Add Opening Cash Brought Forward		7,776	9,482	9,482
Effect of Exchange Rate Changes on Net Cash		68	(81)	(203)
Ending Cash Carried Forward		**13,370**	**15,121**	**7,776**

Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

1 . SUMMARY OF ACCOUNTING POLICIES

The unaudited consolidated interim financial statements ("Interim Financial Statements") presented are those of Pacific Edge Limited ("Company") and its subsidiaries ("Group"). The Company is registered and domiciled in New Zealand. The Group's purpose is to research, develop and commercialise diagnostic and prognostic tools for the early detection and management of cancers. Pacific Edge Diagnostics New Zealand Limited and Pacific Edge Diagnostics USA Limited manage and operate the laboratories used for the detection of bladder cancer. Pacific Edge (Australia) Pty Limited's purpose is the sales and marketing of bladder cancer products research in the Australian market and develop the Cxbladder products and other prognostic tools. Pacific Edge Analytical Services Limited is a dormant entity.

The Company is a for profit entity, registered in New Zealand under the Companies Act 1993 and is a reporting entity for the purposes of the Financial Markets Conduct Act 2013. The Company is dual listed, with its primary listing of ordinary shares quoted in New Zealand on the NZX Main Board, and a secondary listing in Australia as a Foreign Exempt Entity on the ASX.

a) Basis of Preparation of Financial Statements

The Interim Financial Statements for the six months ended 30 September 2026 have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (GAAP) and the Financial Markets Conduct Act 2013. They comply with the New Zealand Equivalents to International Financial Reporting Standards (NZ IFRS) and other guidance as issued by the External Reporting Board, as appropriate for entities, and with International Financial Reporting Standards.

The Interim Financial Statements have been prepared in accordance with NZ IAS 34 - Interim Financial Reporting. In complying with NZ IAS 34, these consolidated Interim Financial Statements also comply with IAS 34 - Interim Financial Reporting and should be read in conjunction with the Company's 2026 Annual Report.

The Interim Financial Statements are prepared on the basis of historical cost, except where otherwise identified. The presentational currency used in the preparation of the financial statements is New Zealand dollars and all values are rounded to the nearest thousand dollars ($000).

b) Accounting Policies and Accounting Estimates

All material accounting policies have been applied on a basis consistent with those used in the audited financial statements of Pacific Edge Limited for the year ended 31 March 2026.

c) Going Concern

The Interim Financial Statements have been prepared on the going concern basis which assumes that the Company and Group will have sufficient cash to pay its debts as they fall due for a period of at least 12 months from the signing of these Interim Financial Statements.

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2026

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

For the six months ended 30 September 2026, the Group incurred a loss after tax of $14.730m (September 2025: $19.116m) and net operating cash outflows of $12.330m (September 2025: $19.026m). As at 30 September 2026, the Company and Group had $29.370m of cash, cash equivalents, and short term deposits on hand (Sept 2025: $22.121m), and net assets of $32.263m (Sept 2025: $26.896m). While the Company and Group continues to incur operating losses, the Company and Group remains solvent and continues to pay its debts as they fall due.

The loss of Medicare Coverage on 24 April 2025* continued to reduce Group revenue and US test volumes for the six months to 30 September 2026. On 4 November 2026* the final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Cxbladder Triage Plus from 20 December 2026. The Directors expect that the reinstatement of Medicare coverage will support increased testing volumes, reimbursement, and revenue generation. However, there remains significant uncertainty regarding the timing and extent of the resulting increase in testing volumes, the level of reimbursement that may be achieved, and the revenue that is generated.

The average cash burn for the six months to 30 September 2026, excluding funds and costs related to capital raising and foreign exchange movements, was $2.208m per month. This provides a cash runway of over 13 months as at 30 September 2026, which would not extend through the full 12-month period from the date of authorisation of these Interim Financial Statements. With the issue of the LCD for microhematuria patients classified as intermediate risk on 4 November 2026, the Board has approved selective investments in the commercial team and digital technologies to support commercial and laboratory operations and strengthen the competitive position in the hematuria market. Responding to the LCD opportunity will involve initial increases in expenditure and cash burn ahead of any associated revenue uplift, potentially reducing the length of the cash runway. If the expected value or timing of the uplift in revenue from the finalised LCD is different to that currently forecast, cash burn could also be adversely affected. Should future forecast cash flows be insufficient to meet obligations as they fall due, the Company may be required to undertake further capital initiatives. Whilst past capital initiatives have been successful, there would be uncertainties regarding the timing, quantum, and success of any future capital raise.

These matters indicate the existence of a material uncertainty as at 30 September 2026 that may cast significant doubt on the Company's and Group's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. Notwithstanding this material uncertainty, the Directors consider that the going concern basis of accounting remains appropriate, having regard to the Group's existing liquidity, their demonstrated ability to manage expenditure, the favourable final LCD, and its history of successful capital initiatives. Accordingly, the Interim Financial Statements have been prepared on a going concern basis and do not include any adjustments that would be necessary if the Company and Group were unable to continue as going concern.

*All dates with an asterisk refer to US dates

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

d) Authorisation

The Interim Financial Statements were authorised by the Board of Directors on 23 November 2026. The Annual Financial Statements for the year ended 31 March 2026 were authorised by the Board of Directors on 22 May 2026.

e) Audit

The Interim Financial Statements for the six months ended 30 September 2026 are unaudited. Comparative balances for 30 September 2025 are unaudited, whilst the comparative balances for 31 March 2026 are audited.

f) Basis of Consolidation

The following entities and the basis of their inclusion for consolidation in these Interim Financial Statements are as follows:

			Ownership Interests & Voting Rights	
Name of Subsidiary	**Place of Incorporation (or registration) and Operation**	**Principal Activity**	**30 Sept 2026 (%)**	**30 Sept 2025 (%)**
Pacific Edge Diagnostics New Zealand Limited	New Zealand	Commercial Sales and Diagnostic Laboratory Operation	100	100
Pacific Edge (Australia) Pty Limited	Australia	Commercial Sales and Biotechnology Research & Development	100	100
Pacific Edge Diagnostics USA Limited	USA	Commercial Sales and Diagnostic Laboratory Operation	100	100
Pacific Edge Analytical Services Limited	New Zealand	Dormant Company	100	100

2. INVESTMENT AND ADVANCES IN SUBSIDIARIES

The consolidated Interim Financial Statements incorporate the assets and liabilities and results of Pacific Edge Diagnostics New Zealand Limited, Pacific Edge (Australia) Pty Limited, Pacific Edge Diagnostics USA Limited, and Pacific Edge Analytical Services Limited, all of which are 100% owned by the Company. Subsidiaries have a 31 March balance date. The investments in and advances to subsidiaries are eliminated on consolidation in the Group financial statements.

3. DIVIDENDS

The Company does not propose to pay dividends to shareholders similar to previous years. This policy continues.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

4. REVENUE AND OTHER INCOME

	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Cxbladder Sales			
- US - Accrual Accounting	3,989	4,115	7,957
- US - Cash Accounting	639	928	1,576
- Total US Sales	4,628	5,043	9,533
- Rest of World	1,228	896	1,966
Total Operating Revenue	**5,856**	**5,939**	**11,499**
Other Income			
Grant Revenue	-	-	46
Research Rebates and Tax Incentives	743	897	1,467
Total Other Income	**743**	**897**	**1,513**

On 24 April 2025*, Local Coverage Determination (L39365) 'Genetic Testing in Oncology: Specific Tests' became effective in the US, halting Medicare coverage of Cxbladder tests.

Pacific Edge reported in its 31 March 2025 Financial Satements that prior to the loss of Medicare coverage, it had generated approximately 60% of its US revenue from Medicare and approximately 56% of total Operating Revenue.

The loss of Medicare Coverage on 24 April 2025* continued to reduce Group revenue and US test volumes for the six months to 30 September 2026. On 4 November 2026* the final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Cxbladder Triage Plus from 20 December 2026 for intermediate risk patients. Re-coverage is expected to provide an uplift in revenue generation and the financial performance of the Company and Group.

Due to the non-coverage, Medicare tests performed during the six months to 30 September have not been accrued in the six months to 30 September 2026. This accounting treatment continues the change in treatment on not accruing Medicare revenue for tests from 24 April 2025.

If following the LCD issue, the Company and Group can reliably calculate revenue, the company may be able to recommence accounting for Medicare tests on an accrual basis for the Financial Statements for the year ending 31 March 2027.

*All dates with an asterisk refer to US dates

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

5. OPERATING EXPENSES

The note below highlights total expenses shown within total operating expenses. These items are then split across functions laboratory, research, sales and marketing and general and administration as reported in the annual report.

	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Operating Expenses			
Amortisation	97	187	372
Auditors Remuneration			
- Group year end financial statements	105	102	203
- Half year review of financial statements	35	35	35
- Travel Costs	6	6	12
Total Auditors Remuneration	**146**	**143**	**250**
Consultant Costs	692	1,121	1,873
Depreciation	397	418	848
Depreciation on Right of Use Assets	709	682	1,391
Directors Fees	314	314	630
Employee Expenses			
– Employee Benefits	9,035	12,383	23,769
– Employee Share Scheme Expenses	1,132	77	77
– Employee Share Options	447	384	869
Total Employee Expenses	**10,614**	**12,844**	**24,715**
Interest on Lease Liabilities	30	76	130
Legal Expenses	165	732	910
NZX / ASX / Registry Fees	143	108	203
Rental and Lease Expense	60	28	123
Site Fees - Clinical Studies	1,523	1,730	3,058
Other Operating Expenses	6,817	7,856	14,855
Total Operating Expenses	**21,707**	**26,239**	**49,358**

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2026

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Employee Share Scheme

Employee Share Scheme Expenses are a non-cash expense. These relate to shares issued to employees in lieu of cash bonuses.

Employee Share Options

Employee Share Options are a non-cash expense. Refer to Note 8 of the Annual Report for details of the accounting policy for Employee Share Schemes.

Other Operating Expenses

The major categories of expenditure which make up operating expenses, but are not disclosed separately above: Laboratory costs, Information Technology costs, Compliance and Regulatory costs, Investor Relations costs.

6. SEGMENT INFORMATION

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer who makes strategic decisions.

There are two operating segments at balance date:

1. **Commercial**: The sales, marketing, laboratory and support operations to run the commercial businesses worldwide; and
2. **Research**: The research and development of diagnostic and prognostic products for human cancer.

The reportable operating segment Commercial derives its revenue primarily from sales of Cxbladder tests and the reportable operating segment Research derives its revenue primarily from grant income. The Chief Executive Officer assesses the performance of the operating segments based on results for the period.

Segment income, expenses and profitability are presented on a gross basis excluding inter-segment eliminations to best represent the performance of each segment operating as independent business units. The segment information provided to the Chief Executive Officer for the reportable segments described above, for the six months ended 30 September 2026 is shown on the following page.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Unaudited 6 Months to 30 September 2026	Commercial ($000)	Research ($000)	Less: Eliminations ($000)	Total External Income ($000)
Income				
Operating Revenue - External	5,856	-	-	5,856
Other Income	520	1,099	(876)	743
Interest Income	9	375	-	384
Foreign Exchange (Loss)	(3)	31	-	28
Unrealised FX Gain on Forward Contracts	-	(34)	-	(34)
Total Income	**6,382**	**1,471**	**(876)**	**6,977**
Expenses				
Other Expenses	7,510	3,268	(876)	9,902
Employee Benefits	5,407	5,197	-	10,604
Depreciation & Amortisation	951	250	-	1,201
Total Operating Expenses	**13,868**	**8,715**	**(876)**	**21,707**
Loss Before Tax	**(7,486)**	**(7,244)**	**-**	**(14,730)**
Income Tax Expense	-	-	-	-
Loss After Tax	**(7,486)**	**(7,244)**	**-**	**(14,730)**
Net Cash Flow to Operating Activities	**(6,606)**	**(5,724)**	**-**	**(12,330)**

Unaudited 6 Months to 30 September 2025	Commercial ($000)	Research ($000)	Less: Eliminations ($000)	Total External Income ($000)
Income				
Operating Revenue - External	5,939	-	-	5,939
Other Income	606	1,251	(960)	897
Interest Income	5	294	-	299
Foreign Exchange Gain	(5)	(7)	-	(12)
Total Income	**6,545**	**1,538**	**(960)**	**7,123**
Expenses				
Other Expenses	8,499	4,579	(960)	12,118
Employee Benefits	7,710	5,124	-	12,834
Depreciation & Amortisation	953	334	-	1,287
Total Operating Expenses	**17,162**	**10,037**	**(960)**	**26,239**
Loss Before Tax	**(10,617)**	**(8,499)**	**-**	**(19,116)**
Income Tax Expense	-	-	-	-
Loss After Tax	**(10,617)**	**(8,499)**	**-**	**(19,116)**
Net Cash Flow to Operating Activities	**(8,948)**	**(10,078)**	**-**	**(19,026)**

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Audited 12 Months to 31 March 2026	Commercial ($000)	Research ($000)	Less: Eliminations ($000)	Total External Income ($000)
Income				
Operating Revenue - External	11,505	-	(6)	11,499
Other Income	1,139	5,219	(4,845)	1,513
Interest Income	9	512	-	521
Foreign Exchange (Loss)	(10)	(10)	-	(20)
Unrealised FX Gain on Forward Contracts	-	67	-	67
Total Income	**12,643**	**5,788**	**(4,851)**	**13,580**
Expenses				
Other Expenses	18,731	8,150	(4,851)	22,030
Employee Benefits	14,677	10,038	-	24,715
Depreciation & Amortisation	1,876	737	-	2,613
Total Operating Expenses	**35,284**	**18,925**	**(4,851)**	**49,358**
Loss Before Tax	**(22,641)**	**(13,137)**	**-**	**(35,778)**
Income Tax Expense	-	-	-	-
Loss After Tax	**(22,641)**	**(13,137)**	**-**	**(35,778)**
Net Cash Flow to Operating Activities	**(20,655)**	**(11,283)**	**-**	**(31,938)**

Eliminations

These are the intercompany transactions between the subsidiaries and the Parent. These are eliminated on consolidation of Group results. The Research segment of the business utilise consumables and other components that are purchased by the Commercial segments of the business, with the costs of these components allocated to Research segment, and the Commercial segment recognising revenue from the sale.

Total Laboratory Throughput:

Unaudited	Commercial # Tests	Research # Tests	Total # Tests
6 months ended 30 September 2026	8,528	1,850	10,378
6 months ended 30 September 2025	10,371	2,820	13,191
12 months ended 31 March 2026	18,783	5,407	24,190

Laboratory Throughput is a key metric for the Group. Laboratory Throughput provides evidence of the usage of Cxbladder products globally and the rates of adoption between different customer segments. Total Laboratory Throughput includes commercial tests, which are invoiced to customers, and research tests which are not considered to be billable as these tests relate to user programs or other non-chargeable activities.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Commercial test numbers are also a key metric for the Group: Commercial Tests are those tests for which the Company is actively seeking reimbursement and cash receipts, and tests performed at no charge in order to gain new customers.

Segment Assets and Liabilities Information:

Unaudited as at 30 September 2026	Commercial ($000)	Research ($000)	Total ($000)
Total Assets	7,096	30,984	38,080
Total Liabilities	2,483	3,334	5,817

Unaudited as at 30 September 2025	Commercial ($000)	Research ($000)	Total ($000)
Total Assets	7,542	27,122	34,664
Total Liabilities	4,151	3,617	7,768

Audited as at 31 March 2026	Commercial ($000)	Research ($000)	Total ($000)
Total Assets	7,499	10,103	17,602
Total Liabilities	3,603	3,340	6,943

Additions to non current assets for the period include:

	Commercial ($000)	Research ($000)	Total ($000)
Property, Plant & Equipment	148	-	148
Right of Use Assets	67	-	67
Intangible Assets	18	-	18
Total Additions to Non Current Assets	**233**	**-**	**233**

The amounts provided to the Chief Executive Officer with respect to total assets and total liabilities are measured in a manner consistent with that of the financial statements. These assets and liabilities are allocated based on the operation of the segment and the physical location of the asset.

There are no unallocated assets or liabilities.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Geographic Split of Revenue and Non-Current Assets

The Group generates most of the operating revenue from Commercial tests from the US and New Zealand and also receives Grant revenue from New Zealand. Rest of World consists of Revenue from Australia and Southeast Asia.

	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Operating and Grant Revenue			
US	4,628	5,043	9,613
New Zealand	1,422	1,375	2,778
Rest of World	549	418	621
Total Operating and Grant Revenue	**6,599**	**6,836**	**13,012**

	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Non-Current Assets			
US	1,105	2,624	1,846
New Zealand	1,757	2,459	1,982
Rest of World	-	1	1
Total Non-Current Assets	**2,862**	**5,084**	**3,829**

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

7. SHARE CAPITAL

	Unaudited Sept 2026 6 Months Shares	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Opening Balance	**1,022,631,578**	**314,157**	**294,458**	**294,458**
Issue of Ordinary Shares				
- Issue of Ordinary Shares - Placement[1]	149,384,548	25,395	16,073	16,073
- Issue of Ordinary Shares - Retail Offer[2]	62,704,581	10,660	4,662	4,662
- Issue of Ordinary Shares - Employee Remuneration[3]	6,661,392	1,132	77	77
- Issue of Ordinary Shares - Exercise of Options[4]	30,758	6	-	31
- Issue of Ordinary Shares - Share Issue Expense[5]	470,588	80	-	63
- Issue of Ordinary Shares - Directors Fees[6]	-	-	151	151
- Issue of Ordinary Shares - Employee Sign-on Incentive[7]	-	-	63	43
Less Share Issue Expense	-	(1,431)	(1,401)	(1,401)
Movement	**219,251,867**	**35,842**	**19,625**	**19,699**
Closing Balance	**1,241,883,445**	**349,999**	**314,083**	**314,157**

[1] During the period 149,384,548 shares were issued resulting from a Share Placement at an average price of $0.170 per share. (2026: 160,728,498 shares at an average price of $0.100 per share)

[2] During the period 62,704,581 shares were issued resulting from a Share Retail Offer at an average price of $0.170 per share. (2026: 46,621,913 shares at an average price of $0.100 per share)

[3] During the period 6,661,392 shares were issued as part of employees' remuneration in lieu of cash payments at an average price of $0.170 per share. (2026: 736,475 shares at an average price of $0.105 per share)

[4] During the period 30,758 shares were issued as a result of employees exercising 60,776 share options at an average exercise price of $0.108 per share (2026: 232,842 shares issued as a result of employees exercising 426,031 share options at an average exercise price of $0.101 per share)

[5] During the period 470,588 shares were issued as Non-cash consideration, being in recognition of providing legal advice during the capital raise at an average price of $0.170 per share. (2026: 625,000 shares at an average price of $0.100 per share)

[6] During the prior period 1,507,600 shares were issued to Directors in lieu of Directors Fees at an average price of $0.100 per share

[7] During the prior period 263,276 shares were issued to employees as non-cash consideration at an average price of $0.165 per share, in recognition of joining the Company as an employee in lieu of a cash incentive

There are 1,241,883,445 ordinary shares on issue. (September 2025: 1,022,135,460; March 2026: 1,022,631,578).

All fully paid shares in the Company have equal voting rights and equal rights to dividends. All Ordinary Shares are fully paid and have no par value.

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2026

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

8. RECONCILIATION OF CASH FLOWS TO OPERATING ACTIVITIES WITH OPERATING NET LOSS

	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Net Loss for the Period	(14,730)	(19,116)	(35,778)
Add Non Cash Items:			
Depreciation	397	418	848
Unrealised FX Gain on Forward Contracts	34	-	(67)
(Profit) on disposal of Property, Plant and Equipment	(1)	(23)	(10)
Amortisation	97	187	372
Employee Share options	447	382	837
Employee bonuses paid in shares in lieu of cash	1,218	140	365
Depreciation on right of use assets	709	682	1,392
Interest on finance leases shown in lease repayments	30	76	130
Total Non Cash Items	**2,931**	**1,862**	**3,867**
Add Movements in Other Working Capital items:			
(Increase) Decrease in Receivables and Other Assets	(178)	1,123	2,757
(Increase) Decrease in Inventory	307	(326)	(433)
(Decrease) in Payables and Accruals	(632)	(2,595)	(2,385)
Effect of exchange rates on net cash	(28)	26	34
Total Movement in Other Working Capital	**(531)**	**(1,772)**	**(27)**
Net Cash Flows to Operating Activities	**(12,330)**	**(19,026)**	**(31,938)**

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

9. NET TANGIBLE ASSETS

Net Tangible Assets per share is a non-GAAP measure that is required to be disclosed by the NZX Listing Rules. The calculation of the Group's Net Tangible Assets per share and its reconciliation to the consolidated balance sheet is presented below.

	Unaudited Sept 2026 6 Months ($000)	Unaudited Sept 2025 6 Months ($000)	Audited March 2026 12 Months ($000)
Total Assets	38,080	34,664	17,602
Less Intangible Assets	343	608	422
Less Total Liabilities	5,817	7,768	6,943
Net Tangible Assets	**31,920**	**26,288**	**10,237**
Number of Shares Issued (000's)	1,241,883	1,022,135	1,022,632
Net Tangible Assets Per Share	**$0.026**	**$0.026**	**$0.010**

10. CONTINGENT LIABILITIES

There were no known contingent liabilities at 30 September 2026 (September 2025: Nil and March 2026: Nil). The Company and Group have not granted any securities in respect of liabilities payable by any other party whatsoever.

11. CAPITAL COMMITMENTS

There are no capital commitments at 30 September 2026 (September 2025: Nil and March 2026: Nil).

12. RELATED PARTIES

Details of all related party relationships have been disclosed in the annual report for the year ended 31 March 2026.

In addition to these disclosures, during the six months to 30 September 2026, shareholders resolved to pay cash of $12,699 to Director Simon Flood, being unpaid Director remuneration that has accrued to him in respect of the period from 19 December 2025 to 31 March 2026.

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2026

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

13. LOCAL COVERAGE DETERMINATION (LCD) CHANGES

On 4 November 2026* the final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Cxbladder Triage Plus from 20 December 2026 for intermediate risk patients. Re-coverage is expected to provide an uplift in revenue generation and the financial performance of the Company and Group.

*All dates with an asterisk refer to US dates

14. SUBSEQUENT EVENTS

On 20 October 2026 Pacific Edge Diganostics USA Limited entered into an extension of the lease for its Hershey facility, which incorporates the US laboratory. The 60 month extension commences 1 December 2026 with a year 1 base rent of US$438,038.

There are no other subsequent events other than the matter disclosed in Note 13 above.

Independent auditor's review report

To the shareholders of Pacific Edge Limited

Report on the consolidated interim financial statements

Our conclusion

We have reviewed the consolidated interim financial statements of Pacific Edge Limited (the Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 30 September 2026, and the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six months ended on that date, and notes, comprising material accounting policy information and other explanatory information.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 30 September 2026, and its financial performance and cash flows for the six months then ended, in accordance with International Accounting Standard 34 *Interim Financial Reporting* (IAS 34) and New Zealand Equivalent to International Accounting Standard 34 *Interim Financial Reporting* (NZ IAS 34).

Basis for conclusion

We conducted our review in accordance with the New Zealand Standard on Review Engagements 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* (NZ SRE 2410 (Revised)). Our responsibilities are further described in the *Auditor's responsibilities for the review of the consolidated interim financial statements* section of our report.

We are independent of the Group in accordance with Professional and Ethical Standard 1 *International Code of Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand)* issued by the New Zealand Auditing and Assurance Standards Board (PES 1), as applicable to audits and reviews of public interest entities. We have also fulfilled our other ethical responsibilities in accordance with PES 1.

Other than in our capacity as auditor and assurance practitioner, we have no other relationships with, or interests in, the Group.

Material uncertainty related to going concern

We draw attention to the disclosures in Note 1c to the consolidated interim financial statements, which describes the Group's continued operating losses and cash outflows, the impact of the loss of US Medicare coverage for its Cxbladder tests and the subsequent publication of a favourable Local Coverage Determination effective from 20 December 2026.

PricewaterhouseCoopers, PwC Centre, 60 Cashel Street,
PO Box 13-244, Christchurch 8141, New Zealand
T: +64 3 374 3000

As described in Note 1c, there are material uncertainties regarding the timing and extent of any uplift in revenue arising from the renewed Medicare coverage, the level of forecasted cash burn and the Group's ability to secure sufficient additional funding should this be required. These events or conditions, along with other matters set forth in Note 1c, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Responsibilities of Directors for the consolidated interim financial statements

The Directors of the Company are responsible on behalf of the Company for the preparation and fair presentation of these consolidated interim financial statements in accordance with IAS 34 and NZ IAS 34 and for such internal control as the Directors determine is necessary to enable the preparation and fair presentation of the consolidated interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the consolidated interim financial statements

Our responsibility is to express a conclusion on the consolidated interim financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the consolidated interim financial statements, taken as a whole, are not prepared in all material respects, in accordance with IAS 34 and NZ IAS 34.

A review of consolidated interim financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated interim financial statements.

Who we report to

This report is made solely to the Company's Shareholders, as a body. Our review work has been undertaken so that we might state those matters which we are required to state to them in our review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's Shareholders, as a body, for our review procedures, for this report or for the conclusion we have formed.

The engagement partner on the review resulting in this independent auditor's review report is Nathan Wylie.

For and on behalf of:



PricewaterhouseCoopers Christchurch
23 November 2026



PacificEdge
CANCER DIAGNOSTICS

87 St David Street, PO Box 56, Dunedin, New Zealand
P 0800 555 563 (NZ) | +64 3 577 6733 (Outside NZ)
F +64 3 974 9393
www.pacificedgedx.com